Almont, 5 mg 98 pcs.

Bronchospasm, Runny nose (rhinitis), Bronchial asthma

Prevention and long-term treatment of bronchial asthma in children, including:

• preventing daytime and nighttime symptoms of the disease (for children 2 years and older);
• Treatment of bronchial asthma in patients with hypersensitivity to acetylsalicylic acid (for children 6 years and older);
• preventing exercise-induced bronchospasm (for children 2 years and older).

Promotion of symptoms of seasonal and year-round allergic rhinitis in children from 2 years of age.

Active ingredient

Montelukast

Composition

Active substance:

Montelukast 5.00 mg (in the form of montelukast sodium 5.20 mg);

Auxiliary substances:

Mannitol 201.20 mg,

microcrystalline cellulose 66.00 mg, <

Hyprolose 9.00 mg,

croscarmellose sodium 9.00 mg,

Pigment Blend PB- 24880 (lactose monohydrate 4.50 mg, iron oxide red dye 0.50 mg) 5.00 mg,

Magnesium stearate 3.00 mg,

aspartame 1.50 mg,

cherry flavoring (Silarom Cherry Flavour 1219813182) 0.10 mg.

How to take, the dosage

Orally, the tablet should be chewed.

Interaction

In patients who received phenobarbital concomitantly, the area under the pharmacokinetic curve “concentration-time” of montelukast decreased by about 40%, but dosage regimen adjustment is not required in these patients. Since montelukast is metabolized by CYP3A4 isoenzyme, caution should be exercised, especially in children, if montelukast is simultaneously used with inducers of CYP3A4 isoenzyme, such as phenytoin, phenobarbital and rifampicin.

Special Instructions

The drug ALMONT is not recommended for the treatment of acute attacks of bronchial asthma. Patients with bronchial asthma are recommended to always carry emergency drugs. When an acute attack occurs, short-acting inhaled beta2-adrenomimetics should be used. Patients should consult their physician as soon as possible if they need more short-acting inhaled beta2-adrenomimetics than usual.

Contraindications

• Hypersensitivity to the active ingredient or any excipient of the product
• children under 2 years of age (for 4 mg doses) and under 6 years of age (for 5 mg doses);
• Patients with rare hereditary diseases: galactose intolerance, lactase deficiency or glucose-galactose malabsorption;
• phenylketonuria (contains aspartame).

.

Side effects

Infectious and parasitic diseases: upper respiratory tract infections.

Overdose

Symptoms of drug overdose in patients with chronic bronchial asthma when administered at a dose greater than 200 mg daily for 22 weeks and at a dose of 900 mg daily for 1 week have not been identified.

There have been reports of acute montelukast overdose (when administered at least 1 g daily) in the post-marketing period and in clinical trials in adults and children. Clinical and laboratory data in this case indicate that the safety profile of the drug in children, adults and elderly patients is consistent. The most frequent symptoms were thirst, drowsiness, vomiting, psychomotor agitation, headache and abdominal pain.

Treatment: administration of symptomatic therapy.

There are no data on the possibility of excretion of montelukast by peritoneal dialysis or hemodialysis.

Pregnancy use

The use of Almont during pregnancy is possible if the estimated benefit to the mother exceeds the potential risk to the fetus.

Similarities

Singular, Montelar, Montelukast, Singlon, Montelukast, Almont, Glémont